Abstract
Cannabigerol (CBG) is a minor, non-psychoactive cannabinoid typically extracted from the plant Cannabis sativa (C. sativa). Utilizing our novel yeast fermentation technology platform, minor cannabinoids such as CBG can be produced in a more sustainable, cost-effective, and timely process as compared to plant-based production. Our aim was to characterize and compare the in vitro activity profile of CBG and the more widely studied Cannabidiol (CBD) in skin and be the first group to test CBG clinically on human skin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
